LSE · RUA.L
RUA Life Sciences plc
£0.28+£0.01 (+2.96%)
RUA Life Sciences plc’s quoted price sits in the upper half of its reported 52-week range, 10.32% below the high.
Loading market information…
LSE · CNSL.L · GBp
Stock price, earnings
Quote as of Oct 30, 2026, 08:45 AM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Cambridge Nutritional Sciences plc’s quoted price sits in the lower half of its reported 52-week range, 47.68% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Cambridge Nutritional Sciences plc’s next earnings report is currently expected on Nov 19, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cambridge Nutritional Sciences plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 1987 and headquartered in London, UK, Cambridge Nutritional Sciences plc (formerly Omega Diagnostics Group PLC until its name change in September 2023) is a specialist in the development, manufacturing, and supply of medical diagnostic products. The company primarily operates within the food sensitivity testing market, creating and producing "Foodprint" branded kits designed to detect immune reactions to food. Beyond manufacturing, it provides clinical analysis services directly to the public, clinics, and healthcare professionals, and also offers the "Food Detective" consumer food test. Its diverse client base includes government entities, private hospitals, reference laboratories, nutritionists, naturopaths, and other medical practitioners. Cambridge Nutritional Sciences plc boasts a global presence, serving markets across the United Kingdom, continental Europe, North, South, and Central America, India, various other Asian countries and the Far East, Africa, and the Middle East.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2023 |
|---|
| Aug 3, 2023 |
| -£0.01 |
| £4.12M |
| Q2 2022 | Nov 24, 2022 | -£0.01 | £3.43M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£0.28+£0.01 (+2.96%)
RUA Life Sciences plc’s quoted price sits in the upper half of its reported 52-week range, 10.32% below the high.
£0.01-£0.00 (-0.92%)
Genedrive Plc’s quoted price sits in the lower half of its reported 52-week range, 37.68% below the high.
£0.01+£0.00 (+4.0%)
CelLBxHealth plc’s quoted price sits in the lower half of its reported 52-week range, 76.79% below the high.
£0.02+£0.00 (+15.75%)
Proteome Sciences plc’s quoted price sits in the lower half of its reported 52-week range, 61.59% below the high.
£0.01-£0.00 (-5.22%)
Cizzle Biotechnology Holdings Plc’s quoted price sits in the lower half of its reported 52-week range, 72.05% below the high.
£0.09-£0.00 (-2.78%)
MyHealthChecked PLC’s quoted price sits in the lower half of its reported 52-week range, 58.33% below the high.
£0.00£0.00 (0.0%)
N4 Pharma Plc’s quoted price sits in the lower half of its reported 52-week range, 52.5% below the high.
£0.00-£0.00 (-12.5%)
Surgical Innovations Group plc’s quoted price sits in the lower half of its reported 52-week range, 41.67% below the high.
